Biktarvy (Bictegrav/Emtricit/Tenofov Ala) Patent Expiration, LOE Window & CMS Spending
Biktarvy (Bictegrav/Emtricit/Tenofov Ala) by Gilead Sciences: FDA Orange Book core substance LOE 2035-06-19 (last listed 2036-11-08), 0 AB generics, $6.68B 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N210251 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2035-06-19 |
| Last Listed Patent or Exclusivity Date | 2036-11-08 |
| Orange Book Patents (*PED Extensions) | 11 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $6.68B |
| 2024 Medicare Part D Spend | $3.46B |
| 2024 Medicaid Spend | $3.22B |
| Reported Wholesale Price Change (CA SB 17) | 9 WAC filings (max 17.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.